BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 31425728)

  • 21. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II. Side-effects.
    Winther L; Malling HJ; Mosbech H
    Allergy; 2000 Sep; 55(9):827-35. PubMed ID: 11003446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections.
    Drachenberg KJ; Wheeler AW; Stuebner P; Horak F
    Allergy; 2001 Jun; 56(6):498-505. PubMed ID: 11421893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study.
    Höiby AS; Strand V; Robinson DS; Sager A; Rak S
    Clin Exp Allergy; 2010 Jul; 40(7):1062-70. PubMed ID: 20642579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study.
    Bødtger U; Poulsen LK; Jacobi HH; Malling HJ
    Allergy; 2002 Apr; 57(4):297-305. PubMed ID: 11906359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation.
    Möbs C; Slotosch C; Löffler H; Jakob T; Hertl M; Pfützner W
    J Immunol; 2010 Feb; 184(4):2194-203. PubMed ID: 20048125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine.
    von Baehr V; Hermes A; von Baehr R; Scherf HP; Volk HD; Fischer von Weikersthal-Drachenberg KJ; Woroniecki S
    J Investig Allergol Clin Immunol; 2005; 15(4):234-41. PubMed ID: 16433203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous apple consumption induces oral tolerance in birch-pollen-associated apple allergy.
    Kopac P; Rudin M; Gentinetta T; Gerber R; Pichler Ch; Hausmann O; Schnyder B; Pichler WJ
    Allergy; 2012 Feb; 67(2):280-5. PubMed ID: 22070352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit.
    Ellis AK; Tenn MW; Steacy LM; Adams DE; Day AG; Walker TJ; Nolte H
    Ann Allergy Asthma Immunol; 2018 May; 120(5):495-503.e2. PubMed ID: 29432967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.
    Hylander T; Latif L; Petersson-Westin U; Cardell LO
    J Allergy Clin Immunol; 2013 Feb; 131(2):412-20. PubMed ID: 23374268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.
    Kopp MV; Brauburger J; Riedinger F; Beischer D; Ihorst G; Kamin W; Zielen S; Bez ; Friedrichs F; Von Berg A; Gerhold K; Hamelmann E; Hultsch ; Kuehr J
    J Allergy Clin Immunol; 2002 Nov; 110(5):728-35. PubMed ID: 12417881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study.
    Pfaar O; Barth C; Jaschke C; Hörmann K; Klimek L
    Int Arch Allergy Immunol; 2011; 154(4):336-44. PubMed ID: 20975285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis.
    Rosewich M; Lee D; Zielen S
    Hum Vaccin Immunother; 2013 Jul; 9(7):1523-31. PubMed ID: 23584250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract--a new therapeutic option for patients with atopic dermatitis.
    Novak N; Thaci D; Hoffmann M; Fölster-Holst R; Biedermann T; Homey B; Schaekel K; Stefan JA; Werfel T; Bieber T; Sager A; Zuberbier T
    Int Arch Allergy Immunol; 2011; 155(3):252-6. PubMed ID: 21293143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
    Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
    Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.
    Patel P; Holdich T; Fischer von Weikersthal-Drachenberg KJ; Huber B
    J Allergy Clin Immunol; 2014 Jan; 133(1):121-9.e1-2. PubMed ID: 23870670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Birch pollen-specific subcutaneous immunotherapy reduces ILC2 frequency but does not suppress IL-33 in mice.
    van Rijt LS; Logiantara A; Canbaz D; van Ree R
    Clin Exp Allergy; 2018 Nov; 48(11):1402-1411. PubMed ID: 30126007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies.
    Mothes N; Heinzkill M; Drachenberg KJ; Sperr WR; Krauth MT; Majlesi Y; Semper H; Valent P; Niederberger V; Kraft D; Valenta R
    Clin Exp Allergy; 2003 Sep; 33(9):1198-208. PubMed ID: 12956739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients.
    Pfaar O; Biedermann T; Klimek L; Sager A; Robinson DS
    Allergy; 2013 Oct; 68(10):1306-13. PubMed ID: 23991896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts.
    Winther L; Malling HJ; Moseholm L; Mosbech H
    Allergy; 2000 Sep; 55(9):818-26. PubMed ID: 11003445
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The adsorption of allergoids and 3-O-desacyl-4'-monophosphoryl lipid A (MPL®) to microcrystalline tyrosine (MCT) in formulations for use in allergy immunotherapy.
    Bell AJ; Heath MD; Hewings SJ; Skinner MA
    J Inorg Biochem; 2015 Nov; 152():147-53. PubMed ID: 26337118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.